A randomized, open label, multi-center study to compare the safety and immunogenicity of BBIL Typbar-TCV to Sanofi Pasteur Typhim Vi, administered intramuscularly to subjects aged 2 to 15 years - Typbar-TCV

Trial Profile

A randomized, open label, multi-center study to compare the safety and immunogenicity of BBIL Typbar-TCV to Sanofi Pasteur Typhim Vi, administered intramuscularly to subjects aged 2 to 15 years - Typbar-TCV

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Pharmacodynamics
  • Sponsors Bharat Biotech
  • Most Recent Events

    • 12 Sep 2016 Status changed from recruiting to completed.
    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top